ClinicalTrials.gg

Program

pralatrexate

Also written as “Pralatrexate Injection”, “Pralatrexate” and “Folotyn”.

Its studies are mostly in Lymphoma, T-Cell, Peripheral · Carcinoma, Non-Small-Cell Lung · Lymphoma, T-Cell, Cutaneous · Hematologic Neoplasms · Lymphoma, B-Cell, led by 3 companies.

Furthest: phase 4, since Sep 19, 202319 company-led studies, 2 open or runningNext primary completion: Feb 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Aurobindo Pharma122 open or runningphase 3since Sep 19, 2023Aug 14, 2006Feb 2027phase 1 · NCT07036133
Zydus Lifesciences40 open or runningphase 3since Aug 18, 2011Jan 24, 2003none ahead
Mundipharma30 open or runningphase 4since May 5, 2017Dec 4, 2013none ahead

Also a collaborator on its studies: axis-clinicals-limited.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 5 studies since Jan 24, 2003.

  1. Jul 23, 2008Phase 2 study in Carcinoma, Transitional CellAurobindo Pharma · NCT00722553 · 30 enrolled · United States, Argentina, Belgium and more
  2. Oct 19, 2009Phase 2 study in Lymphoma, B-CellZydus Lifesciences · NCT00998946 · 29 enrolled · United States
  3. May 5, 2010Phase 2 study in Breast NeoplasmsAurobindo Pharma · NCT01118624 · 22 enrolled · United States, Czechia, France and more
  4. May 28, 2010Phase 1 study in Lymphoma, T-Cell, CutaneousAurobindo Pharma · NCT01134341 · 34 enrolled · United States, Italy
  5. Aug 18, 2011Phase 3 study in Lymphoma, T-Cell, PeripheralZydus Lifesciences · NCT01420679 · 21 enrolled · United States, Australia, Belgium and more
  6. Feb 7, 2013Phase 1 study in Lymphoma, Non-HodgkinAurobindo Pharma · NCT01789723
  7. Mar 21, 2013Phase 1 study in Carcinoma, Non-Small-Cell LungAurobindo Pharma · NCT01820091
  8. Dec 4, 2013Mundipharma's first study: phase 2 study in Lymphoma, T-Cell, PeripheralNew to MundipharmaMundipharma · NCT02013362 · 25 enrolled · Japan
  9. Mar 28, 2014Phase 2 study in Lymphoma, T-Cell, PeripheralAurobindo Pharma · NCT02106650 · 36 enrolled · United States
  10. Sep 25, 2015Phase 1 study in Lymphoma, T-Cell, PeripheralAurobindo Pharma · NCT02594267 · 48 enrolled · United States
  11. Jul 26, 2016Phase 3 study in Lymphoma, T-Cell, PeripheralMundipharma · NCT03349333 · 85 enrolled · China
  12. May 5, 2017Phase 4 study in Lymphoma, T-Cell, PeripheralMundipharma · NCT03150602 · 22 enrolled · Taiwan
  13. Sep 19, 2023Phase 3 study in Lymphoma, T-Cell, PeripheralAurobindo Pharma · NCT06072131 · 504 enrolled · United States, Canada, Germany and more
  14. Mar 18, 2025Phase 1 study in Hematologic NeoplasmsAurobindo Pharma · NCT07036133 · 24 planned · United States

Ahead

  1. Feb 2027Primary completion: phase 1 study in Hematologic NeoplasmsAurobindo Pharma · NCT07036133
  2. Jul 2030Primary completion: phase 3 study in Lymphoma, T-Cell, PeripheralAurobindo Pharma · NCT06072131

TargetBeta

DHFR →RFC1 →read by rule
“A folate analogue inhibitor of dihydrofolate reductase (DHFR) exhibiting high affinity for reduced folate carrier-1 (RFC-1) with antineoplastic and immunosuppressive activities”NCIt, by rule
“Dihydrofolate reductase inhibitor”ChEMBL 37, by rule

Studies

All 19 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07036133Hematologic Neoplasms · United States1RecruitingAurobindo PharmaFeb 202724
NCT06072131Lymphoma, T-Cell, Peripheral · United States, Canada, Germany and more3Active, not recruitingAurobindo PharmaJul 2030504
NCT03150602Lymphoma, T-Cell, Peripheral · Taiwan4UNKNOWNMundipharmaDec 31, 202022
NCT03349333Lymphoma, T-Cell, Peripheral · China3CompletedMundipharmaJul 21, 201785
NCT02594267Lymphoma, T-Cell, Peripheral · United States1CompletedAurobindo PharmaApr 7, 201748
NCT02106650Lymphoma, T-Cell, Peripheral · United States2CompletedAurobindo PharmaOct 201836
NCT02013362Lymphoma, T-Cell, Peripheral · Japan2CompletedMundipharmaDec 201525
NCT01820091Carcinoma, Non-Small-Cell Lung1WithdrawnAurobindo PharmaApr 20150
NCT01789723Lymphoma, Non-Hodgkin1WithdrawnAurobindo PharmaMar 20150
NCT01420679Lymphoma, T-Cell, Peripheral · United States, Australia, Belgium and more3TerminatedZydus LifesciencesDec 201721
NCT01134341Lymphoma, T-Cell, Cutaneous · United States, Italy1CompletedAurobindo PharmaAug 201534
NCT01118624Breast Neoplasms · United States, Czechia, France and more2CompletedAurobindo PharmaApr 201222
NCT00998946Lymphoma, B-Cell · United States2CompletedZydus LifesciencesAug 201229
NCT00722553Carcinoma, Transitional Cell · United States, Argentina, Belgium and more2CompletedAurobindo PharmaApr 201130
NCT00606502Carcinoma, Non-Small-Cell Lung · United States, Argentina, Brazil and more2CompletedZydus LifesciencesJun 24, 2010201
NCT00554827Lymphoma, T-Cell, Cutaneous · United States1CompletedAurobindo PharmaJan 201255
NCT00481871Recurrence · United States2CompletedAurobindo PharmaMay 2011119
NCT00364923Lymphoma, T-Cell, Peripheral · United States, Belgium, Canada and more2CompletedAurobindo PharmaJan 2009115
NCT00052442Lymphoma · United States2CompletedZydus LifesciencesMar 200972

How it is read

Names in the registry

  • “Pralatrexate Injection”, 9 entries
  • “Pralatrexate”, 4 entries
  • “pralatrexate”, 2 entries
  • “Folotyn”, 2 entries
  • “Folotyn and Leucovorin”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.